Feature | Drug-Eluting Balloons | November 02, 2017

Drug-eluting Balloon is Noninferior to Drug-eluting Stent in Patients With In-stent Restenosis

Results of the DARE Trial were presented at TCT 2017

The B. Braun Sequent Please drug-eluting balloon.

An illustration of the Sequent Please drug-coated balloon.

DARE trial results presented at TCT 2017 show drug coated balloons are equal to the Xience stent in treating restenosis.

November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug-eluting bAlloon for in-stent Restenosis) multicenter, randomized clinical trial evaluated the performance of the B. Braun Sequent Please drug-eluting balloon (DEB) vs. the Abbott Xience everolimus-eluting stent (EES) in patients with ISR. The study found the DEB was non-inferiority to the drug-eluting stent (DES).

“In this largest trial of DEB versus DES for any ISR to date, the use of a DEB was non-inferior in terms of in-segment minimal lumen diameter at six-month follow-up,” said Jose P.S. Henriques, M.D., Head of the Catheterization Laboratory at the Academic Medical Center, University of Amsterdam in Amsterdam, The Netherlands. “Future research is warranted to investigate the safety and efficacy of the DEB as compared to DES for ISR in adequately powered, large-scale randomized clinical trials.”  

A total of 278 patients of whom 56% had DES-ISR were randomized at eight sites to treatment with DEB (N=141) or DES (N=137). 

Henriques said the results showed non-inferiority of Sequent Please DEB vs. Xience for any ISR. There was greater acute gain with DES vs. DEB, but this was offset by greater DES late loss at six-month follow-up. 

“The DEB appears to be an alternative therapy for any ISR negating the need for additional stent,” Henriques said. “There were no differences in clinical endpoints, including TVR.”

He added that the study results confirm the European guidelines that list DEBs as a Class 1A therapy for in-stent restenosis. 

As compared with DEB, DES was associated with larger minimal lumen diameter (MLD) and lower percent stenosis immediately post-procedure (1.84±0.46 vs. 1.72±0.35, P=0.018 and 26±10% vs. 30±10%, P=0.03). Angiographic follow up was completed at 196±53 days in 79% of patients. With respect to the primary endpoint of in-segment MLD at six months, DEB was non-inferior to DES (DEB 1.71±0.51.mm vs. DES 1.74±0.61.mm, P-noninferiority <0.0001), with a lesser degree of late loss compared to DES (0.17±0.41 vs. 0.45±0.47, P<0.001). Target vessel revascularization at 12-month follow-up was similar in both groups (DES 7.1 vs. DEB 8.8%, P=0.65).

The DARE study was an investigator-initiated study funded by the Academic Medical Center - University of Amsterdam and supported by an unrestricted research grant from B. Braun. Dr. Henriques reported receiving an unrestricted research grant from BBraun.

The results of the DARE study were published simultaneously in JACC: Cardiovascular Interventions.

For more information: www.crf.org

Related Content

TCT Announces 2017 Late-breaking Clinical Trial Presentations



Jan Baan, Bimmer E. Claessen, Kirsten Boerlage-van Dijk, et al. “A Randomized Comparison of Paclitaxel-eluting Balloon Versus Everolimus-eluting Stent for the Treatment of Any In-stent Restenosis: The DARE Trial.” JACC: Cardiovascular Interventions October 30, 2017, 3513; DOI: 10.1016/j.jcin.2017.10.024



Related Content

Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score Percutaneous Transluminal Angioplasty (PTA) Scoring Sheath platform for use in iliac, ilio-femoral, popliteal, infra-popliteal and renal arterial plus synthetic and/or native arteriovenous hemodialysis fistula. This is a new type of scoring balloon technology.
News | Balloon Catheter | June 04, 2020
June 4, 2020 — Transit Scientific announced the U.S.
NC Trek RX Coronary Dilatation Catheter is part of an FDA Class I recall because it may not defalte.
News | Balloon Catheter | February 24, 2020
February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters
Edwards Lifesciences Recalls IntraClude Intra-aortic Occlusion Device
News | Balloon Catheter | July 15, 2019
Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon rupture during...
Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval
Technology | Balloon Catheter | August 23, 2018
W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Gore...
Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...